Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-09-15), Foresee Pharmaceuticals Co's 3-1 Month Momentum % is 1.79%.
The industry rank for Foresee Pharmaceuticals Co's 3-1 Month Momentum % or its related term are showing as below:
ROCO:6576's 3-1 Month Momentum % is ranked worse than 55.83% of 1021
companies
in the Drug Manufacturers industry
Industry Median: 2.79
vs ROCO:6576: 1.79
Foresee Pharmaceuticals Co (ROCO:6576) 3-1 Month Momentum % Explanation
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Foresee Pharmaceuticals Co 3-1 Month Momentum % Related Terms
ROCO:6576 vs ZTS: 3-1 Month Momentum % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Foresee Pharmaceuticals Co's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Foresee Pharmaceuticals Co 3-1 Month Momentum % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Foresee Pharmaceuticals Co's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Foresee Pharmaceuticals Co's 3-1 Month Momentum % falls into.
Foresee Pharmaceuticals Co (ROCO:6576) 3-1 Month Momentum % Calculation
3-1 Month Momentum % is calculated as following:
3-1 Month Momentum %
=
( Price 1-month ago
/
Price 3-month ago
- 1 )
*
100 %
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Foresee Pharmaceuticals Co (ROCO:6576) has a 3-1 Month Momentum % of 1.79% as of Sep. 15, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Foresee Pharmaceuticals Co and its competitors. According to the industry distribution chart, Foresee Pharmaceuticals Co ranks #570 out of 1021 companies in the Drug Manufacturers industry, placing it in the top 55.8%.
Is Foresee Pharmaceuticals Co's 3-1 Month Momentum % too high?
Foresee Pharmaceuticals Co's current 3-1 Month Momentum % is 1.79%. The Drug Manufacturers industry median 3-1 Month Momentum % is 2.79. Foresee Pharmaceuticals Co's value of 1.79% is 35.8% below this industry median. Based on the distribution chart, Foresee Pharmaceuticals Co ranks #570 out of 1021 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Foresee Pharmaceuticals Co has a GF Score™ of 67/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Foresee Pharmaceuticals Co's 3-1 Month Momentum % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Foresee Pharmaceuticals Co ranks #570 out of 1021 companies for 3-1 Month Momentum %. This places Foresee Pharmaceuticals Co in the lower half of its industry. The industry median 3-1 Month Momentum % is 2.79. Foresee Pharmaceuticals Co's value of 1.79% is 35.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Drug Manufacturers company?
The median 3-1 Month Momentum % among Drug Manufacturers companies is 2.79, based on 1,021 companies in the industry. Companies in the top quartile (top 25%) have a 3-1 Month Momentum % significantly above this median, while those in the bottom quartile fall well below. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Foresee Pharmaceuticals Co's current 3-1 Month Momentum % of 1.79% is 35.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Foresee Pharmaceuticals Co and its competitors. For the Drug Manufacturers industry, the median 3-1 Month Momentum % is 2.79 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Foresee Pharmaceuticals Co's current 3-1 Month Momentum % is 1.79%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Foresee Pharmaceuticals Co stock overvalued right now?
Based on GuruFocus' analysis, Foresee Pharmaceuticals Co (ROCO:6576) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$92.29, compared to a current price of NT$81.90 — trading 11.3% below its estimated fair value. The current 3-1 Month Momentum % is 1.79% and 35.8% below the Drug Manufacturers industry median of 2.79. Foresee Pharmaceuticals Co's overall GF Score™ is 67/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Foresee Pharmaceuticals Co (ROCO:6576), the current 3-1 Month Momentum % is 1.79% as of Sep. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Foresee Pharmaceuticals Co (ROCO:6576) Overvalued in 2026?
Based on GuruFocus' analysis, Foresee Pharmaceuticals Co stock appears to be undervalued.
The current stock price of NT$81.90 is trading 11.3% below its estimated GF Value™ of NT$92.29.
GuruFocus considers Foresee Pharmaceuticals Co to be Modestly Undervalued.
Key valuation signals for ROCO:6576:
3-1 Month Momentum %: 1.79%
GF Value™: NT$92.29 vs. price of NT$81.90 (11.3% below fair value)
Industry Position: 35.8% below the Drug Manufacturers median (#570 of 1021)
No single metric tells the full story. See the ROCO:6576 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Foresee Pharmaceuticals Co Ltd main activity is applying stabilized injectable formulation (SIF) platform technology to produce products for anticancer and treatment of chronic diseases. Its pipeline includes CAMCEVI (Leuprolide, FP-001), FP-014 (Triptorelin), Aderamastat (FP-025, MMP-12 Inhibitor), Linvemastat (FP-020, MMP-12 Inhibitor), and others. The Group operates business only in a single industry of new drug development, and all of its revenue is generated from Taiwan.
67GF Score
Get the complete analysis for ROCO:6576
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6576 has been successfully added to your 
